Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
+$0.04 today
- Market cap
- $3.04B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
Volume 2.56M
Average 1.66M
Balance Sheet
Inspect the capital base behind the business.
Assets
$383.53M
FY 2025 · Annual
+18.7% YoYLiabilities
$369.84M
FY 2025 · Annual
+4.9% YoYEquity
$13.69M
FY 2025 · Annual
Balance Sheet
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 67.27M | 121.97M | 67.45M | 71.62M | 111.04M |
| Short-term Investments | 35.16M | 0 | 5M | 0 | 0 |
| Net Receivables | 17.46M | 30.83M | 39.2M | 40.42M | 51.05M |
| Inventory | 18.12M | 24.74M | 38.84M | 48.18M | 68.67M |
| Other Current Assets | 0 | 9.29M | 5.78M | 7.45M | 9.55M |
| Total Current Assets | 142.6M | 186.82M | 156.26M | 167.66M | 240.31M |
| Property, Plant & Equipment (Net) | 6.63M | 9.51M | 29.18M | 28.21M | 27.06M |
| Goodwill | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M |
| Intangible Assets | 131.45M | 120.61M | 109.76M | 98.92M | 88.08M |
| Long-term Investments | 0 | 0 | 0 | 4.12M | 0 |
| Tax Assets | 0 | 0 | 0 | 6.09M | 0 |
| Other Non-current Assets | 829K | 4.73M | 4.54M | (4.81M) | 5.22M |
| Total Non-current Assets | 161.77M | 157.7M | 166.34M | 155.4M | 143.21M |
| Total Assets | 304.36M | 344.52M | 322.6M | 323.06M | 383.53M |
| Account Payables | 8.92M | 4.61M | 11.57M | 2.29M | 3.08M |
| Short-term Debt | 0 | 0 | 0 | 15.1M | 6.23M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 25.63M | 27.23M | 51.43M | 39.75M | 100.27M |
| Total Current Liabilities | 79.04M | 73.62M | 95.19M | 100.44M | 109.57M |
| Long-term Debt | 88.07M | 187.08M | 190.93M | 217.01M | 31.53M |
| Deferred Tax Liabilities | 4.94M | 3.52M | 2.27M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 37.08M | 25.72M | 6.23M | 1.97M | 228.73M |
| Total Non-current Liabilities | 130.09M | 225.71M | 234.19M | 252.23M | 260.26M |
| Total Liabilities | 209.13M | 299.34M | 329.38M | 352.68M | 369.84M |
| Common Stock | 13K | 14K | 14K | 15K | 17K |
| Retained Earnings | (460.11M) | (554.77M) | (617.03M) | (671.86M) | (671.31M) |
| Accumulated OCI | (31K) | (23K) | (25K) | (25K) | (25K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 95.23M | 45.19M | (6.78M) | (29.62M) | 13.69M |
| Total Debt | 88.07M | 198.06M | 229.19M | 271.45M | 37.76M |
| Net Debt | 20.8M | 76.09M | 161.74M | 199.83M | (73.28M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $111.8M |
| Receivables | $56.3M |
| Inventory | $74.2M |
| Other Current | $9.4M |
| Total Current Assets | $251.7M |
| PP&E (Net) | $27.0M |
| Goodwill | $22.9M |
| Intangible Assets | $85.4M |
| Long-term Investments | $4.0M |
| Other Non-current | $1.1M |
| Total Non-current Assets | $140.3M |
| Total Assets | $392.0M |
Analysis
Selected assets total $392.0M for Latest. The largest visible component is Cash & Equivalents at $111.8M, about 28.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 |
How much cash does XERS have?
Xeris Biopharma Holdings, Inc. (XERS) reported $111.04M in cash and equivalents in fiscal 2025.
How much debt does XERS carry?
Xeris Biopharma Holdings, Inc. (XERS) reported $37.76M of total debt, with net debt of -$73.28M.
Continue the stock analysis
Jump to another research area for this company.